Danaher (DHR)
(Real Time Quote from BATS)
$263.50 USD
+4.24 (1.64%)
Updated May 15, 2024 12:56 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DHR 263.50 +4.24(1.64%)
Will DHR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DHR
Danaher (DHR) Rides on Business Strength Amid Headwinds
Danaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
DHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Markel (MKL) Q1 Earnings, Revenues Miss Estimates, Rise Y/Y
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
Other News for DHR
Novo Nordisk owner to acquire major stake in Australian life sciences firm
Danaher Corp: An Exploration into Its Intrinsic Value
Danaher Corporation (DHR) Presents at BofA Securities 2024 Health Care Conference Call Transcript
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
My Dividend Growth Portfolio: Selling Bio-Pharma And Buying More Big-Tech